NXgenPort is addressing an unmet need in cancer care by remotely monitoring patients between chemotherapy treatments with a Software as a Medical Device (SaMD) and an implanted Smart Port with intravascular cytometry sensors. By using machine learning to measure blood cell counts, vitals, and heart function in vivo, NXgenPort will alert physicians to early signs of infection, determine readiness for next treatment, and improve health equity and access. With the acceleration of Hospital at Home, care providers, cancer researchers, and pharma stakeholders find value in monitoring a patient’s biological response to interventions with a robust data package to improve outcomes.

### Highlights
- Built device prototype and tested it with human and swine blood
- Compared device results to a gold standard lab test
- Raised $1.125M to date
- All IP owned by NXgenPort: Filed three patent applications – one Utility (issued Q4:’23), one Utility (published), and one provisional
- Three years of a collaboration agreement with Mayo Clinic
- Completed Mayo Clinic Platform Accelerate [Aug 2023]
- Built, trained and tested model for predicting neutropenia risk
- Accepted to MedTech Innovator [June 2023]
- Completed pre-clinical animal model testing [March 2023]
- Completed premier mHUB Accelerator in Chicago [May 2022]
- Verified existing CPT codes for reimbursement
- FDA strategy: Class I, 510(k) for hardware & software
- Beach-head market: early detection of neutropenia

### Investment
- **$2 M Seed Round (open)**
- **$12M Series A (Q3:2024)**

### Use of Funds
- Product Development & Validation Testing
- Intellectual Property & Patent Fees
- Engineering, Regulatory, Quality Hires
- Quality Management System
- Animal models
- Pre-submission to FDA
- Other Working Capital

### Previous Investors
- Baxter
- Edward Elmhurst Ventures
- Mayo Clinic
- Angels, HWI, F&F, Founders
- mHUB

### Leadership

#### CATHY SKINNER
Chief Executive Officer
Led three startups in oncology, focused on investor relations, and strategic partnerships

#### ROSANNE WELCHER, PHD, MBA
Chief Operating Officer
+30 years in companion diagnostics and cancer, 50 products through FDA and 16 patents

#### KELLY CHRISTIAN, MS
VP R&D Engineering
+30 years in med device development, 30 patents in ports

#### JOHN SLUMP
Board Chair
Serial entrepreneur, two exits for $140M and $800M

### Contact
Cathy@NXgenPort.com
651-587-5440

### Technology
- Microelectronics with a power source in the body of the port and a fiber optic bundle through the wall of the catheter.
- Autofluorescence illuminates the field and captures images of the blood cells as they flow by the fiber optic tip at the end of the catheter.
- Images are processed by a trained machine learning algorithm that counts the cells based on their known size and composition.
- Real-time, longitudinal data is analyzed and shared with physicians through an API to the electronic medical record so they can intervene before a problem escalates to hospitalization.

### Competition

<table>
<thead>
<tr>
<th>Feature</th>
<th>NXgenPort</th>
<th>Market Leader 1</th>
<th>Market Leader 2</th>
<th>Market Leader 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Automated device</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Remote patient monitoring</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Digital health platform</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Oxygen, heart rate, body temperature</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Patient data collection</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Active remote blood count &amp; heart function</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

### Market
- TAM: 19 B
  - 19 M cancer patients diagnosed around the world annually
- SAM: $3 B
  - 3 M cancer patients in US receive a port and/or high-risk systemic therapy (oral targeted agents, immunotherapy, cellular therapies - CAR-T)
- SOM: $750 M
  - 25% of the market; <CMS new tech add-on; managed services; data analytics

### Timeline

<table>
<thead>
<tr>
<th>Milestone</th>
<th>Date</th>
<th>Cash Outlay</th>
</tr>
</thead>
<tbody>
<tr>
<td>FDA 510(k) Submission</td>
<td>12/18/2025</td>
<td>$30,071,808</td>
</tr>
<tr>
<td>Software as a Medical Device Release</td>
<td>4/28/2026</td>
<td>$3,282,894</td>
</tr>
<tr>
<td>FDA 510(k) Clearance</td>
<td>9/6/2026</td>
<td>$13,282,894</td>
</tr>
<tr>
<td>Production Ready</td>
<td>1/13/2026</td>
<td></td>
</tr>
<tr>
<td>1st Commercial Sale</td>
<td>1/5/2027</td>
<td>$18,516,825</td>
</tr>
<tr>
<td>Profitability</td>
<td>4/1/2028</td>
<td>$25,771,962</td>
</tr>
</tbody>
</table>

### Collaborations

#### Mayo Clinic Platform Accelerate
- [Aug 2023]

#### MedTech Innovator
- [June 2023]

#### mHUB Accelerator
- [May 2022]

#### CPT Codes
- Verified existing CPT codes for reimbursement

#### Patent Applications
- Filed three patent applications – one Utility (issued Q4:’23), one Utility (published), and one provisional

#### Clinical Trials
- Completed pre-clinical animal model testing [March 2023]

#### Clinical Partnerships
- Completed Mayo Clinic Platform Accelerate [Aug 2023]

#### Product Development
- Built device prototype and tested it with human and swine blood

#### Regulatory
- Accepted to MedTech Innovator [June 2023]

#### Clinical Data
- Images are processed by a trained machine learning algorithm that counts the cells based on their known size and composition.

#### Patient Monitoring
- Real-time, longitudinal data is analyzed and shared with physicians through an API to the electronic medical record so they can intervene before a problem escalates to hospitalization.

### NXgenPort
A combination medical device plus software company harnessing the power of machine learning and remote patient monitoring for physicians to proactively manage at-risk cancer patients with an implanted Smart Port that detects early signs of infection and readiness for next treatment.

**Founded:** 2020
**Website:** NXgenPort.com
**Headquarters:** St Paul, MN